{"preliminary_commentary":{"by_channel":{"x_thread":9,"youtube":1,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03427827\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["camrelizumab"]],"indication":"locoregionally advanced nasopharyngeal carcinoma","name":"DIPPER","nct_id":"NCT03427827","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=dipper-nct03427827. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"DIPPER","arms":[{"description":"Patients randomized to this arm will receive PD-1 antibody (SHR-1210), 200mg, ivdrip (\\>30 minutes), d1, q3w × 12 cycles, begining at 4-6 weeks after chemoradiation","label":"Adjuvant PD-1 antibody arm","type":"EXPERIMENTAL"},{"description":"Patients randomized to this arm will receive best supportive care after chemoradiation","label":"Best supportive care","type":"NO_INTERVENTION"}],"collaborators":[],"completion_date":{"date":"2026-02","type":"ESTIMATED"},"conditions":["Nasopharyngeal Neoplasms"],"enrollment":{"count":450,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Camrelizumab","otherNames":["SHR-1210"],"type":"DRUG"}],"last_update":"2024-04-09","lead_sponsor":"Sun Yat-sen University","official_title":"Camrelizumab (PD-1 Antibody) Compared With Best Supportive Care After Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: a Multi-center, Randomised Controlled, Phase 3 Trial (DIPPER)","overall_status":"UNKNOWN","phases":["PHASE3"],"primary_completion_date":{"date":"2024-02-06","type":"ACTUAL"},"primary_outcomes":[{"measure":"failure-free survival","timeFrame":"3 years"}],"references":[{"citation":"Huang SW, Liang YL, Tao YL, Li WF, Zhou GQ, Mao YP, Guo R, Chen L, Xu S, Liu X, Zhang N, Liu F, Shen LF, Zhou YY, Yuan YW, Zou GR, Jin F, Tang LL, Sun Y, Li YQ, Ma J, Liu N. Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials. J Clin Oncol. 2026 Apr 10;44(11):1028-1039. doi: 10.1200/JCO-25-02111. Epub 2026 Mar 6.","pmid":"41791006","type":"DERIVED"},{"citation":"Liang YL, Liu X, Shen LF, Hu GY, Zou GR, Zhang N, Chen CB, Chen XZ, Zhu XD, Yuan YW, Yang KY, Jin F, Hu WH, Xie FY, Huang Y, Han F, Tang LL, Mao YP, Lu LX, Sun R, He YX, Zhou YY, Long GX, Tang J, Chen LS, Zong JF, Jin T, Li L, Lin J, Huang J, Gong XY, Zhou GQ, Chen L, Li WF, Chen YP, Xu C, Lin L, Huang SH, Huang SW, Wang YQ, Huang CL, Feng HX, Hou M, Chen CH, Zheng SF, Li YQ, Hong SB, Jie YS, Li H, Yun JP, Zang SB, Liu SR, Lin QG, Li HJ, Tian L, Liu LZ, Zhao HY, Li JB, Lin AH, Liu N, Zhang Y, Guo R, Ma J, Sun Y. Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial. JAMA. 2025 May 13;333(18):1589-1598. doi: 10.1001/jama.2025.1132.","pmid":"40079940","type":"DERIVED"},{"citation":"Huang SW, Jiang W, Xu S, Zhang Y, Du J, Wang YQ, Yang KY, Zhang N, Liu F, Zou GR, Jin F, Wu HJ, Zhou YY, Zhu XD, Chen NY, Xu C, Qiao H, Liu N, Sun Y, Ma J, Liang YL, Liu X. Systemic longitudinal immune profiling identifies proliferating Treg cells as predictors of immunotherapy benefit: biomarker analysis from the phase 3 CONTINUUM and DIPPER trials. Signal Transduct Target Ther. 2024 Oct 23;9(1):285. doi: 10.1038/s41392-024-01988-w.","pmid":"39438442","type":"DERIVED"}],"start_date":{"date":"2018-07-02","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma","url":"https://clinicaltrials.gov/study/NCT03427827"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/dipper-nct03427827"}